相关实验视频
Updated: Jul 23, 2025

08:18
A Model of Chronic Nutrient Infusion in the Rat
Published on: August 14, 2013
12.8K
低剂量脂多糖诱导高血糖大鼠尿蛋白持续明显增加和潜在的机制
Mulan Wang1,2, Qin Gong1,2, Chenliang Zha1
1Department of Pharmacy, State Key Laboratory of Innovative Drugs and Efficient Energy-Saving Pharmaceutical Equipment, Nanchang, China.
PloS one
|July 19, 2023
概括
低剂量脂聚糖 (LPS) 在高血糖大鼠中迅速诱导稳定的蛋白尿. 这个模型通过模仿通过NF-κB信号传递的损伤和炎症来帮助糖尿病病的研究.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
背景情况:
- 糖尿病病 (DN) 的特征是蛋白尿,但传统模型显示蛋白尿发育缓慢且不稳定.
- 建立快速和稳定的动物模型对于理解DN病原体和测试治疗干预措施至关重要.
研究的目的:
- 为了研究低剂量脂多糖 (LPS) 在诱导快速和稳定的蛋白尿的有效性,在高血糖的小鼠模型.
- 在糖尿病的背景下阐明LPS诱导的蛋白尿和病理的潜在机制.
主要方法:
- 在使用高脂肪食和注射链毒素 (STZ) 的老鼠中诱导高血糖症.
- 一剂LPS (0.8毫克/公斤) 的次损伤剂量通过腹膜内给已确定的高血糖大鼠.
- 测量了尿液中的微专蛋白,质细胞蛋白 (尼弗林,波多辛),炎症因子 (IL-18,NF-κB),亡蛋白和专蛋白 (ALB). 通过定期酸 Schiff (PAS) 染色来评估脏病理.
主要成果:
- 服用LPS导致尿路微专蛋白 (umALB) 的显著和持续增加.
- 在皮层中观察到质细胞蛋白 (尼弗林,波多辛) 和NF-κB的表达有显著的变化.
- 在髓中检测到IL-18,Caspase-1,NF-κB和ALB的水平增加. 病理学检查显示了质底膜加厚,管扩张和上皮细胞脱落.
结论:
- 低剂量的LPS有效地在高血糖大鼠中建立了一个快速而稳定的蛋白尿模式.
- 由LPS引起的蛋白尿与球底膜和管状上皮细胞损伤有关.
- 炎症反应,涉及NF-κB信号通路,在观察到的损伤中起着关键作用,使这种模型对DN研究具有价值.
相关概念视频
Glucagon-like Receptor Agonists
360
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
360
Insulin Secretory Vesicles
5.0K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
5.0K
Nephrotic Syndrome I : Introduction
9
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
9
Hormones Regulating Blood Glucose
3.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.6K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Dipeptidyl Peptidase 4 Inhibitors
213
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
213

